Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Propanc Biopharma, Inc.

Get SEC filing alerts via email and in your feed for Propanc Biopharma, Inc.

PPCB

Propanc Biopharma, Inc.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. is a biopharmaceutical company developing innovative proenzyme therapies targeting solid tumors, including pancreatic, ovarian, and colorectal cancers. Its lead product, PRP, aims to prevent cancer recurrence and metastasis by eradicating cancer stem cells through differentiation therapy. The company focuses on early-stage clinical development, leveraging proprietary formulations, strategic partnerships, and intellectual property to offer safer, potentially first-in-class cancer treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Propanc Biopharma, Inc.

1
1
Propanc Biopharma, Inc. Propanc Biopharma Reports $6.36 Million Net Loss in Q3 Fiscal 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Propanc Biopharma, Inc. Propanc Biopharma Reports $8.9 Million Net Loss for Six Months Ending December 31, 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Propanc Biopharma, Inc. Propanc Biopharma Reports No Revenue and Increased Operating Expenses in Latest 10-Q Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Propanc Biopharma, Inc. Propanc Biopharma Reports $58.9 Million Net Loss and No Revenue for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 8 months ago | 0 comments

5
1
Propanc Biopharma, Inc. Propanc Biopharma Reports No Revenue and Increased Losses in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Propanc Biopharma, Inc. Propanc Biopharma Reports $784K Net Loss, Focuses on Cancer Treatment Development

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Propanc Biopharma, Inc. Propanc Biopharma Reports Mixed Financial Results for Q3 2024, Focuses on Cancer Treatment Development

Via official filing (AI summary) | over 1 year ago | 0 comments